Skip to content

Research at St Andrews

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer

Research output: Contribution to journalArticle

Author(s)

Grant D. Stewart, Thomas Powles, Christophe Van Neste, Alison Meynert, Fiach O'Mahony, Alexander Laird, Dieter Deforce, Filip Van Nieuwerburgh, Geert Trooskens, Wim Van Criekinge, Tim De Meyer, David James Harrison

School/Research organisations

Abstract

Background: Genetic intratumoral heterogeneity (ITH) hinders biomarker development in metastatic clear cell renal cancer (mccRCC). Epigenetic relative to genetic ITH or the presence of consistent epigenetic changes following targeted therapy in mccRCC have not been evaluated. The aim of this study was to determine ITH of the methylome relative to genetic ITH and to evaluate specific epigenetic and genetic changes associated with sunitinib. Patients and methods: Multi-region DNA sampling performed on sequential frozen pairs of primary tumor tissue from 14 metastatic ccRCC patients, in the Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients with Metastatic Renal Cancer: a Pilot Phase II Study (SuMR; ClinicalTrials.gov identifier: NCT01024205), at presentation (biopsy) and after 3-cycles of 50mg sunitinib (nephrectomy). Untreated biopsy and nephrectomy samples before and after renal artery ligation were controls. Ion Proton sequencing of 48 key ccRCC genes, and MethylCap-seq DNA methylation analysis was performed, data was analysed using R. Results: Unsupervised hierarchical clustering revealed complete methylomeclustering of biopsy and three nephrectomy samples for each patient (14/14 patients). For mutational status, untreated biopsy and all treated nephrectomy samples clustered together in 8/13 (61.5%) patients. Only methylation target significantly altered following sunitinib therapy was VHL promoter region 7896829 which was hypermethylated with treatment (FDR=0.077,P<0.001) and consistent for all patients (pre-treatment 50% patients had VHL mutations, 14% patients VHL hypermethylation). Renal artery ligation did not affect this result. No significant differences in driver or private mutation count found with sunitinib treatment. Conclusions: Demonstration of methylome homogeneity and consistent VHL hypermethylation, after sunitinib, overcome the hurdle of ITH present at other molecular levels.
Close

Details

Original languageEnglish
Number of pages10
JournalOncotarget
Volume7
Issue number18
DOIs
Publication statusPublished - 23 Mar 2016

    Research areas

  • Heterogeneity, Methylation, Mutations, Renal cancer, VHL

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome

    Ried, T., Meijer, G. A., Harrison, D. J., Grech, G., Franch-Expósito, S., Briffa, R., Carvalho, B. & Camps, J., 6 Aug 2019, In : Molecular Aspects of Medicine. 69, p. 48-61 14 p.

    Research output: Contribution to journalArticle

  2. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031

    Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In : Scientific Reports. 9, 13 p., 7643.

    Research output: Contribution to journalArticle

  3. Raman spectroscopy investigation of biochemical changes in tumor spheroids with aging and after treatment with staurosporine

    Jamieson, L. E., Harrison, D. J. & Campbell, C. J., May 2019, In : Journal of Biophotonics. 12, 5, e201800201.

    Research output: Contribution to journalArticle

Related by journal

  1. A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT

    Brown, J. L., Shovman, M., Robertson, P., Boiko, A., Goltsov, A., Mullen, P. & Harrison, D. J., May 2017, In : Oncotarget. 8, 18, p. 29657-29667 11 p.

    Research output: Contribution to journalArticle

  2. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

    Meehan, J., Ward, C., Turnbull, A., Bukowski-Wills, J., Finch, A., Jarman, E. J., Xintaropoulou, C., Martinez-Perez, C., Gray, M., Pearson, M., Mullen, P., Supuran, C. T., Carta, F., Harrison, D. J., Kunkler, I. H. & Langdon, S., 2017, In : Oncotarget. 8, 26, p. 42857-42875

    Research output: Contribution to journalArticle

  3. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

    Khalil, H. S., Langdon, S. P., Goltsov, A., Soininen, T., Harrison, D. J., Brown, J. & Deeni, Y. Y., 2016, In : Oncotarget. 7, 46, p. 75874-75901

    Research output: Contribution to journalArticle

  4. Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis

    Zeissler, M-L., Eastwood, J., McCorry, K., Hanemann, C. O., Zajicek, J. P. & Carroll, C. B., 27 Jun 2016, In : Oncotarget. 7, 29, p. 46603-46614 12 p.

    Research output: Contribution to journalArticle

ID: 241554791